Introduction
Characterization of dendritic cells (DCs) as highly efficient antigen-presenting cells (APCs) led to a number of clinical studies showing the benefit of induction of tumor-specific immune responses in cancer patients. 1 However, in sharp contrast to the results obtained in animal models, complete and long-lasting remissions were observed only in a fraction of patients. [2] [3] [4] [5] Largescale application of DC-based vaccines is significantly complicated by the fact that clinical grade DCs are difficult to produce in large quantities, cannot be efficiently expanded ex vivo, and are highly sensitive to cryopreservation. 5 Suboptimal quantities of DCs are frequently used in clinical trials. The lack of adequate cell numbers is most profound in pediatric patients and in patients with low bone marrow reserves. [6] [7] [8] [9] In addition, only a fraction (o1%) of exogenously transferred DCs seems to migrate to the draining lymph nodes, whereas most remain at the site of immunization. 10, 11 This precludes effective use of DCs as vehicles for the delivery of costimulatory factors such as cytokines and chemokines to the organized secondary lymphoid tissue, the primary site of induction of T-cell responses. Identification of alternative sources of APCs for active immunization complementing the use of DCs is a high priority in the field. B cells represent a promising alternative to DCs as cellbased vaccines for immunotherapy. 5, [12] [13] [14] Large numbers of autologous B cells can be easily prepared from the blood of patients and further expanded ex vivo up to 1000-fold in the presence of CD40L. 14 Although only about 10 6 DCs can be prepared from 10 ml of blood, 10 9 -10 10 B cells can be generated from the same volume. Importantly, in contrast to DCs, intravenously administered B cells readily migrate to immune inductive sites in secondary lymphoid tissues. Activated B cells can be loaded with antigen by pulsing with peptides, proteins, tumor lysates, transfection with DNA or RNA, or transduction with viral vectors. 6, 13, 15, 16 Multiple studies have shown that antigen-presenting activated B cells induce potent expansion of antigen-specific CD4 + and CD8 + T cells in vitro. 5, 6, [12] [13] [14] [15] [17] [18] [19] [20] [21] [22] However, with the exception of studies utilizing re-arranged immunoglobulin molecule-encoding antigenic epitopes in the complementarity determining regions, 17, 20 most reports suggest that immunization with B cells pulsed with antigenic peptides or transfected to express whole antigenic proteins fails to induce significant cytotoxic T-cell responses. [23] [24] [25] Thus, optimal B-cell vaccination strategy eliciting cytotoxic T-cell responses remains to be established.
In this study, we show that B cells activated through the toll-like receptor-9 (TLR-9) and CD40 receptors exhibit powerful APC capacity in vitro. We show that immunization with as few as 5 Â 10 4 genetically modified live B cells stably expressing antigen results in an induction of functional cytotoxic T-cell responses in vivo. Importantly, we show that immunization with B cells stably expressing model antigen, but not with peptidecoated B cells, protects hosts against tumor growth in a therapeutic setting. Thus, it is likely that prolonged antigen presentation and delivery by proliferating B cells are required for an efficient immunization. As lentivirally transduced cellular vaccines are increasingly used in gene therapy and cancer immunotherapy clinical trials, the data presented here provide evidence supporting the use of genetically modified B cells as a promising candidate for a cellular vaccine for cancer immunotherapy and an alternative complementing the use of DCs, especially in pediatric patients and patients with low bone marrow reserves.
Results
B cells activated through TLR-9 and CD40 receptors efficiently present antigen to CD8 + and CD4 + T cells in vitro
We addressed whether the antigen-presenting capacity of B cells can be enhanced by a combination of signals send through the surface immunoglobulin receptor, CD40 receptor, and a 'danger' signal transmitted by the TLRs. As shown in Figure 1 , stimulation of B cells with TLR-9 receptor ligand CpG motif-containing oligonucleotide (CpG), activating anti-CD40 antibodies (a-CD40), or TLR-4 ligand LPS significantly increased the expression of major histocompatibility complex (MHC)-I, MHC-II, and costimulatory molecules CD80 (B7.1) and CD86 (B7.2). In contrast, stimulation with antibodies engaging surface immunoglobulin (a-Ig) alone or in combination No stim. B-cell-based cellular vaccine S Guo et al with other stimuli did not increase the expression of molecules involved in antigen presentation. Surface CD62L (L-selectin), a homing molecule involved in the targeting of lymphocytes to secondary lymphoid tissues, was down-modulated by all activating stimuli. Levels of CCR7 chemokine receptor and a4b7 integrin were not significantly affected by any treatment (Figure 1 and data not shown). Importantly, the levels of antigen-presenting and costimulatory molecules on B cells activated with CpG, a-CD40, or their combination resembled those detected on LPS-matured DCs (Figure 1 ).
MHC-I
Next, we assessed the in vitro antigen-presenting capacity of activated B cells. B cells pulsed with ovalbumin-derived MHC-I H-2K b -restricted OVA-1 peptide and MHC-II I-A b -restricted OVA-2 peptide were incubated at various B:T cell ratios with CD8 + T cells and CD4 + T cells isolated from transgenic mice expressing respective cognate T-cell receptors (OT-1 and OT-2). Although B cells stimulated either with CpG or a-CD40 antibody alone that displayed increased ability to induce specific T-cell proliferation, the effect was markedly enhanced by combined stimulation (Figure 2a ). Surprisingly, B cells stimulated with anti-Ig antibody alone or in combination with CpG and a-CD40 displayed lower APC capacity than CpG/CD40-stimulated B cells ( Figure 2b ). Similar results were obtained with stimulator B cells derived from transgenic mice stably expressing OVA under a control of a ubiquitous promoter.
Compared with peptide-pulsed or transgenic DCs, CPG/CD40-activated B cells were about 50% as effective in inducing T-cell proliferation at high APC:T cell ratios; however, DCs were significantly more effective at lower ratios (Figure 2c ). To exclude a possible confounding effect of DCs contaminating B-cell preparations, B cells isolated by a negative selection for CD43 À cells combined with a subsequent depletion of CD11c + cells or by a positive selection of CD19 + cells were tested. Although these procedures eliminated almost all contaminating DCs (o0.1% CD11c + cells present in the CD19 + cell preparation), the method of B-cell purification did not have any significant effect on the rate of proliferation of OT-1 or OT-2 cells (Supplementary Figure 1 ). Thus, the observed APC activity is mediated by B cells. In conclusion, B cells activated with CpG and a-CD40 efficiently expand antigen-specific T cells in vitro and can be utilized as APCs for ex vivo expansion of tumor-specific T cells for adoptive T-cell therapy.
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The interaction between APC and specific T cell is regulated by a complex interplay of costimulatory and inhibitory signals mediated by an array of cell surface molecules and soluble factors. In our system, the efficacy of stimulation of proliferation of antigen-specific CD8 + T and CD4 + T cells seemed to best correlate with the expression of CD86 (B7.2), rather than the expression of MHC-I or II (Figure 1 ). However, an effect of other factors cannot be excluded.
IL-12 produced by activated B cells does not affect T-cell proliferation in vitro
Under certain conditions, activated B cells can produce IL-12, 26-29 a cytokine known to direct the differentiation of CD4 + T cells toward the Th1 phenotype and stimulate the proliferation of CD8 + T cells. 30, 31 We assessed whether IL-12 might mediate some of the effect of CpG/CD40activated B cells on antigen-specific T-cell proliferation in vitro. B cells stimulated with CpG expressed the limiting p70 component of IL-12 as well as IL-10 (Figures 3a and b). In contrast, stimulation with LPS resulted in the production of IL-10 without significant production of IL-12. Costimulation through surface immunoglobulin in a combination with a-CD40 and CpG significantly increased the levels of IL-12p70 produced. Importantly, antibody-mediated neutralization of IL-12 did not affect the rate of proliferation of OT-1 or OT-2 cells or production of IFN-g or IL-4 (Figures 3c and d and data not shown). Thus, the ability of activated B cells to induce antigen-specific T-cell proliferation in vitro is not significantly affected by the production of costimulatory IL-12. However, IL-12 produced by B cells might have a function in vivo, for example by modulating NK-cell activity, modifying cytokine expression by T cells, exerting anti-angiogenic effect, and inducing chemokines and other regulatory factors modulating T-cell trafficking and duration of conjugation events between CD8 + T cells and APCs. 32 
B cells stably expressing antigen induce functional CTL responses in vivo
Next, we tested whether immunization with peptidepulsed fresh or activated B cells induces endogenous T-cell responses in naïve recipients. Intravenous administration of 5 Â 10 4 to 2 Â 10 6 OVA-1 and OVA-2 peptidepulsed fresh or activated B cells resulted in low CD8 + T-cell responses as determined by ICS staining and pentamer-binding assays (data with 10 6 B cells presented in Figure 4a ). In sharp contrast, immunization with as few as 5 Â 10 4 resting or activated OVA-transgenic B cells stably expressing antigen induced OVA-1-specific CD8 + T cells at frequencies ranging from 0.5 to 1.5% of total CD8 + T cells in the spleen and lymph nodes ( Figure 4a and data not shown). OVA-2-specific CD4 + T cells were induced at lower frequencies (0.1-0.2% of total CD4 + T cells). Foot pad immunization with 2 Â 10 4 to 5 Â 10 4 CpG/CD40-activated OVA-transgenic B cells resulted in an induction of 0.5-3% of OVA-1-specific T cells of all CD8 + splenocytes (data not shown). Surprisingly, activation status of B cells before administration did not have a significant effect on the magnitude of the ensuing T-cell responses. Similarly, intravenously administered OVAtransgenic DCs were more effective at inducing CD8 + T-cell response than peptide-pulsed DCs (Figure 4a ), consistently with earlier reports. 29, 33 Compared with immunization with activated OVA-transgenic DCs, immunization with activated B cells induced lower frequencies of antigen-specific CD8 + T cells (LPS-DCs versus CpG/CD40-B cells, P ¼ 0.04). However, this difference could be compensated by administering higher doses of antigen-expressing B cells. We intentionally used low numbers of B cells for immunization, as this better represents the cell number per kg body weight ratio typically used in clinical protocols.
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To address the functionality of T-cell responses induced by immunization with fresh or activated B cells, in vivo cytotoxicity assay was performed. Although immunization with 10 6 unstimulated or stimulated autologous B cells pulsed with OVA-1 peptide failed to induce detectable CTL responses, immunization with as few as 5 Â 10 4 OVA-transgenic B cells resulted in efficient killing of target cells in vivo ( Figure 4b ). Similarly, immunization with transgenic DCs was more efficient in CTL induction than immunization with peptidepulsed DCs. These results were confirmed by ex vivo killing assays using splenocytes and lymph node cells as effector cells (data not shown).
To test whether antigenic peptide-pulsed CpG/CD40activated B cells can sustain proliferation of existing antigen-specific T cells in vivo, B6 mice were injected with OT-1 transgenic T cells labeled with CFSE and, 24 h later, with fresh or activated B cells pulsed with OVA-1 and OVA-2 peptides. Adoptively transferred CD8 + OT-1 T cells efficiently proliferated after in vivo stimulation; CD4 + OT-2 cells proliferated to a lower degree ( Figure 5a ). Interestingly, there was little difference in the rate of proliferation of antigen-specific T cells stimulated by non-activated versus activated B cells. 
Activated B cells are less efficient in homing to secondary lymphoid tissues
Observed difference in the antigen-presenting capacity of fresh versus activated B cells in vitro is in a sharp contrast with their comparable immunogenicity in vivo. Possible factors contributing to this discrepancy include decreased capacity of activated B cells to home to secondary lymphoid organs. To determine their homing properties, CFSE-labeled fresh and activated B cells were injected I.V. into recipient mice and the frequencies of CD19 + CFSE + cells in various lymphoid organs were determined 4 and 24 h later ( Figure 6a and data not shown). Compared with unstimulated B cells, activation of B cells with CpG and a-CD40 significantly decreased their ability to home to the spleen, peripheral (PLN) and mesenteric (MLN) lymph nodes and Peyer's patches (PP). This data suggest that the inability of CpG/CD40-activated B cells to induce stronger immune responses in vivo despite their superior APC capacity in vitro may be caused in part by their inefficient homing to secondary lymphoid organs. 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 Naïve C57Bl/6 mice were immunized intravenously with 5 Â 10 4 autologous CpG/CD-40-activated B cells that were not pulsed, pulsed with OVA-1 peptide, nucleofected with EGFP and empty control plasmids, nucleofected with EGFP and OVA-expressing plasmids, or with CpG/CD-40-activated B cells from OVAtransgenic mice that were either not irradiated or exposed to a lethal dose of radiation. OVA-specific immune response was determined in splenocytes 10 days later by ICS and pentamer-binding assays.
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The altered homing capacity of activated B cells could be caused by a down-regulation of CD62L molecule from the cell surface occurring as early as 30 min after activation (Figure 1b ). To address the role of CD62L in B-cell trafficking, homing experiments were performed using B cells from selectin-deficient mice (Sel-l,p,e À/À ). Although freshly isolated B cells from selectin-knockout mice readily migrated to the spleen of recipient animals, homing to PLN and MLN was severely reduced (P ¼ 0.01 and 0.003 for PLN and MLN compared with control B6 B cells) (Figure 6b ). After stimulation with CpG+CD40 antibody, selectin-knockout B cells exhibited diminished capacity to home to the spleen, and virtually no activated cells were found in PLNs, MLNs, or PP (Figure 6b, right panel) . Thus, the loss of the ability of activated B cells to home to PLN, MLN, and PPs can be partially attributed to decreased surface levels of selectin.
Next, we investigated whether decreased lymphoid tissue homing of activated B cells can be reversed by expression of proteolysis-resistant mutant of CD62L. The sheddase-mediated proteolysis occurs within the membrane-proximal region between R 283 and S 284 of CD62L. 34 We have constructed a CD62L mutant in which the proteolysis is inhibited by a substitution of the membrane-proximal region of CD62L with that of P-selectin lacking the cleavage site (Figure 6c ). 35 CpG/CD40-stimulated B-cells nucleofected with plasmid-encoding CD62L-SR expressed about 2.5-fold higher mean levels of total surface CD62L ectodomain compared with cells nucleofected with wild-type CD62L as determined by flow cytometry. Expression of CD62L-SR resulted in an increased migration of activated B cells to PLN and MLN (Figure 6d ). These results confirm the role of CD62L in targeting B cells to secondary lymphoid organs and provide possible means for the enhancement of the immunogenicity of genetically modified B-cell-based vaccines. However, simple co-transfection of plasmids encoding antigen and CD62L-SR did not significantly increase in vivo immunogenicity of transfected B cells (data not shown). Stable expression of both proteins by proliferating cells is likely needed for enhanced immunogenicity.
Immunization with antigen-expressing B cells confers protection against tumor growth in a therapeutic setting
To investigate the ability of antigen-presenting B cells to protect against tumor, mice were inoculated subcutaneously with 10 6 EG-7 thymoma cells expressing OVA protein. 3 Figure 7b ). In contrast, only one of five mice immunized with fresh B cells was free of palpable tumor. The ability to control tumor growth correlated with the frequency of OVA-specific CD8 + T cells after the two rounds of immunization, suggesting a direct role of CTLs in tumor protection (P ¼ 0.002; Figure 7c ). In contrast, therapeutic immunization with peptide-pulsed B cells did not significantly increase the frequency of OVAspecific CD8 + T cells or confer protection against tumor (Figure 7d ). This data show that stable expression of antigen by B cells is required for the protection against tumor growth.
Discussion
Since large number of B cells can be easily prepared from relatively small volume of blood, B-cell-based cellular vaccines represent a highly promising approach to the immunotherapy of cancer complementing the use of DCs, especially in select groups of patients such as pediatric patients and patients with low bone marrow reserves. In this report, we show that: (1) activated B cells produce IL-12 and display potent antigen-presenting properties in vitro and in vivo; (2) therapeutic immunization with low numbers of genetically modified B cells stably expressing antigen results in a protection against tumor growth; and (3) B cells can be genetically modified to deliver the antigen to organized lymphoid tissue. Although these results need to be further confirmed by studies using relevant tumor antigens in animal models and in human beings, this report presents an initial set of conditions for the utilization of B cell-based cellular vaccines for the immunotherapy of cancer and other chronic diseases.
To break immune evasion, strong antigenic stimuli comprising multiple antigenic epitopes presented at immune induction sites distant from the immunosuppressive environment of the tumor is needed. In tumor-bearing host, functional TAA-specific effector T cells are continuously depleted by processes of functional exhaustion and activation-induced cell death. 8 Therefore, in contrast to vaccination against infectious agents, in which limited number of immunizations is sufficient to build up immune memory, successful immunotherapy of cancer will likely require multiple immunizations over prolonged period of time not only to induce, but also maintain functional effector T-cell population. [8] [9] [10] Suboptimal induction of immune responses, because of the limited quantity of APCs and short time scale of immunizations, may be some of the major factors responsible for the limited efficacy of most cancer immunotherapy vaccines. In this respect, B cells represent a promising novel platform for cancer immunotherapy, as they can be easily prepared in large numbers. 5, [12] [13] [14] Furthermore, B cells can be easily cryopreserved and retain their antigen-presenting capacity on recovery, thus simplifying clinical procedures for repeated immunizations. 14 Immunization with B cells will likely have to be performed in combination with other therapies that offset the suppressive environment of the tumor, such as therapies blocking the suppressive effect of cytokines and regulatory T cells or drugs inducing immunogenic death of cancer cells. 1, 36, 37 Transduction with lentiviral vectors represents an efficient approach for generating B cells stably producing specific tumor antigens. Recently developed third generation of lentiviral vectors transduces primary cells with high efficiency, does not express any viral protein, and contains a multitude of safety features preventing the generation of replication-competent recombinants or oncogenic transformation. 38 Several reports have shown that DCs transduced with antigen-encoding lentiviral vectors induce strong and long-lasting T-cell responses 29, 33 and several clinical trials currently evaluate the safety and efficacy of lentiviral vectors in cancer immunotherapy. 38 Interestingly, Russo et al. 39 have shown that immunization of mice with 4-10 Â 10 6 lymphocytes transduced with a retroviral vector-encoding tumor antigen resulted in an induction of anti-tumor immunity through cross-presenting host DCs. Here, we show that restricting antigen expression to activated B cells allows efficient immunization with as few as 5 Â 10 4 cells, that is Â 100 lower cell dose. We are currently testing the efficacy of immunization with B cells transduced with lentiviral vectors co-expressing antigen and CD62L-SR. In addition, non-viral modes of genetic modification of somatic cells such as Sleeping beauty transposon are currently under development. 40 As activated B cells pulsed with antigenic peptides or transfected with antigen-expressing plasmid or RNA efficiently present antigen and induce specific T-cell proliferation in vitro and in vivo, it was believed that this simple manipulation would result in an effective cellbased vaccine. 6, 13, 15, 16, 21 However, the data presented here and elsewhere 23, 24 suggest that peptide-pulsed or transfected B cells fail to induce protective CTLs in vivo. Importantly, we show that stable antigen expression is required for an effective vaccine. Multiple studies suggest that the presentation of MHC-I/peptide complexes by peptide or protein-loaded APCs is relatively short lived 41, 42 and epitopes derived from stabilized proteins are more efficiently cross-presented than epitopes derived from rapidly degrading proteins or short peptides. 43 Sustained source of antigen provided by a cellular vaccine is advantageous for T-cell induction because of the prolonged direct presentation or crosspresentation by host DCs. 29, 33 A number of reports have suggested that persistent antigen expression is required for optimal expansion of CD8 + T cells and their differentiation into the memory phenotype. 29, [44] [45] [46] [47] Despite these observations, majority of currently undergoing clinical trials evaluating the efficacy of DC-based immunotherapy use DCs loaded with antigenic peptides, proteins, or tumor lysates. The requirement of sustained antigen expression is likely more critical for B-cell-based vaccines because of the shorter presentation half-time of MHC-peptide complexes on the surface of B cells compared with mature DCs. 42 The difference between DCs and B cells could explain the current lack of reports on the efficacy of B-cell immunization in vivo, despite an abundance of data on their ability to sustain T-cell proliferation in vitro.
There is limited amount of data available regarding the capacity of B cells to induce protective CTL responses in vivo. Ritchie et al. 23 showed that mice immunized intravenously with peptide-loaded CD40L-activated B cells displayed a short delay in the growth of tumor expressing the corresponding epitope; however, no effect was observed in mice administered with freshly isolated B cells or B cells activated with LPS. Importantly, the adhesion-based procedure for B-cell purification used in this report could not preclude DC contamination. Lee et al. 24 has shown that immunization with B cells transfected with mRNAs encoding antigen and costimulatory molecules failed to induce CTLs and tumor protection, despite their potent APC activity in vitro.
Controversy exists in the field as to whether or not resting B cells can serve as APCs. Several groups have shown that these cells induce T-cell tolerance resulting in decreased immune responses in vivo. [48] [49] [50] Although the reason for this seems to be low expression of accessory and costimulatory molecules, Evans et al. 51 suggested that unstimulated B cells are deficient in later functions necessary for a productive T-cell response. Our results suggest that the immunization with low numbers of untouched B cells isolated using a negative selection procedure induces CTLs in vivo; however, the anti-tumor B-cell-based cellular vaccine S Guo et al responses seem to be diminished compared with that induced by activated B cells. It is well established that B cells can internalize antigen through their surface Ig receptors and drive priming of naïve CD4 + T cells in vivo. 52, 53 During a T-helper cell-dependent B-cell response, activated antigen-specific CD4 + T cells express CD40L and in turn activate B cells through the CD40 receptor. After activation, B cells migrate to the B/T-zone boundary in organized lymphoid tissue and greatly improve their ability to present antigen by up-regulating surface MHC and costimulatory molecules. 28, 52, 54 Activation through CD40 receptor dramatically increases the antigen-presenting ability of normal and malignant B cells and has, therefore, been studied as an approach to generate autologous APCs for immunotherapy. 14 CD40activated B cells not only expand antigen-specific CD4 + and CD8 + T cells, but also prime naïve T cells in vitro. 13, 15, 16 In addition to CD40L, B cells can be activated with a number of TLR ligands resulting in enhanced expression of MHC, costimulatory molecules, IL-12, and increased cytoskeletal activity. 26, 27, 55 The B-cell receptor-induced expression of TLR-9 in naïve B cells prevents the polyclonal activation in primary response, as it restricts stimulation to antigen-specific cells. 56 Here, we show that co-stimulation of B cells with CD40L and TLR-9 ligand results in an increase of expression of MHC and costimulatory molecules and enhancement of their ability to sustain specific T-cell proliferation in vitro. This observation may be valuable for protocols using B cells as APCs for the ex vivo expansion of T cells for passive adoptive T-cell immunotherapy. It remains to be established whether B cells activated with CpG alone would be sufficient for induction of tumor protection in human beings. As CpG-stimulated B cells readily expand in vitro, immunotherapy with CpG-activated B cells represents an affordable alternative to more complex technologies involving amplification of B cells on CD40L-expressing cell lines. 57 Recently, it has been reported that IgD + CD27 À naïve mature B cells can uptake DNA by a process of spontaneous transgenesis turning B cells into functional APCs by up-regulation of MHC class I and II, CD40, and CD86. 17, 20 Using a re-arranged immunoglobulin molecule encoding well-defined CD4 + and CD8 + epitopes in the complementarity determining regions, Gerloni et al. have shown that single intravenous injection of as few as 70-300 transfected B cells induced protection against a lethal dose of influenza virus. 17, 20 It is unclear whether spontaneous transgenesis might be associated with chromosomal integration events.
Multiple lines of evidence suggest that the antigen delivered by cellular vaccines is presented by the recipient's secondary lymphoid organ-resident DCs by the process of cross-presentation. 43, [58] [59] [60] B cells can present antigen both by direct presentation and crosspresentation. 17, 23 Gerloni et al. 17 showed that immunization with B lymphocytes transfected with antigenencoding plasmid elicited similar CD4 + and CD8 + T-cells responses in relB À/À and control mice suggesting that transgenic B cells can directly activate T cells in the absence of functional DCs. Furthermore, although the CD4 + T-cell response after a single injection of B cells from MHC-II À/À mice was virtually abolished compared with controls, immunization with MHC-I À/À B cells induced CD8 + T-cell response that was only partially reduced compared with that induced by normal B cells. 17 These results, further confirmed by Ritchie et al., 23 suggest that although the CD4 + T cells are primed directly by transgenic B cells used for immunization, priming of CD8 + T cells occurs by a combination of crosspresentation and direct presentation mechanisms. As B cells activated through various pathways differ in their APC function and homing properties, the importance of cross-priming may vary depending on their activation phenotype. In the experiments presented here, B cells activated by various stimuli displayed large differences in their capacity to stimulate specific T-cell proliferation in vitro; however, their in vivo immunogenicity was comparable. This might be explained by a fact that B cells stably expressing antigen serve to a large degree as a source of antigen for cross-presentation by endogenous APCs; therefore, the type of in vitro stimulation preceding administration is less important for the resulting immunogenicity.
A significant advantage of B cells as APCs in vivo is that they spontaneously home to organized lymphoid tissue, the optimal site of induction of immune responses. The lymph node microenvironment enhances the likelihood that antigen-loaded APCs will encounter naïve and memory CD4 + and CD8 + T cells, whereas APCs in peripheral tissues are more likely to encounter effector memory T cells. Migration from the bloodstream into lymph nodes occurs through a multistep adhesion cascade regulated by tissue-specific chemokines and adhesion receptors facilitating the capture and arrest of lymphocytes from flowing blood. 61 B lymphocytes express CD62L, LFA-1, and CCR7 molecules that have a crucial function in the entering of lymph nodes from blood by extravasation through HEVs expressing peripheral node addressin, CCL21, and ICAM-1. 62,63 CD40activated B cells express surface CCR7 and CXCR4 and decreased levels of CCR5 and CCR6. 64 This pattern of expression suggests that CD-40-activated B cells should enter the T-cell rich areas of secondary lymphoid organs rather than the germinal centers. 62 The first step in entering the lymph node is the tethering and rolling of naïve lymphocytes on the surface of HEVs of PLNs mediated by CD62L. 63, 65, 66 Here, we show that the capacity of B cells to home to secondary lymphoid tissue is diminished after activation through TLR-9 and CD40 likely because of the shedding of CD62L from the cell surface. Decreased homing to secondary lymphoid organs, the primary site of induction of T-cell responses, may be in part responsible for the lack of any advantage of CpG/CD40-activated B cells compared with B cells stimulated with any agent alone in CTL induction, despite their superior antigen-presenting capacity in vitro. The possibility of enhancing the antigenpresenting ability of B cells by various genetic modifications has been addressed by several investigators. Palena et al. 19 has shown that infection of CD40-activated B cells with fowlpox recombinant vector expressing a triad of costimulatory molecules, B7-1, ICAM-1, and LFA-3, significantly improves their function as APCs. Similarly, Biagi et al. 67 have shown that molecular transfer of CD40 and OX40 ligands to leukemic B cells enhances their ability to expand tumor-reactive cytotoxic T cells. Transduction of a chimeric E/L selectin expressing the ectodomain of CD62L into mature DCs has been shown to enhance homing of DCs to PLNs. 68 Here, we show that In summary, immunization with activated autologous B cells presenting defined tumor antigens in combination with other therapies that offset the immunosuppressive environment created by the tumor represent a promising alternative strategy for the immunotherapy and prevention of cancer. Thanks to their availability, activated B cells can be used to test whether repetitive immunization over extended periods of time can overcome tumor tolerance and sustain long-term maintenance of functional anti-tumor T-cell responses.
Materials and methods

Materials
OVA-1 (OVA 257-264 , SIINFEKL) and OVA-2 (OVA 323-339 , ISQAVHAAHAEINEAGR) peptides were synthesized by Genemed Synthesis (South Francisco, CA, USA), CpG oligonucleotide (ODN 1668; TCCATGACGTTCCT GATGCT) by Invitrogen (Carlsbad, CA, USA). LPS was purchased from Sigma (St Louis, MO, USA). Anti-CCR7 antibody was purchased from Biolegend (San Diego, CA, USA); all other antibodies from BD Pharmingen (San Diego, CA, USA), Mice C57BL/6 (B6), B6/SJL, OVA-specific TCR-transgenic OT1 and OT2, OVA-transgenic mice expressing chicken OVA under the control of chicken b-actin promoter/ CMV immediate-early enhancer (# 005145), and selectinknockout mice (Sel-l,p,e À/À , # 003817) were obtained from the Jackson Laboratory (Bar Harbor, Maine; all mice on B6 background). All experimental procedures were approved by the Institutional Animal Care and Use Committee.
B cell and DC purification and stimulation
B cells were purified from the spleen and lymph node cells by negative selection for CD43 À cells on MACS column (Milteneyi Biotec, Auburn, CA, USA) according to manufacturer's directions resulting in 96-98% purity of untouched CD19 + cells. In some experiments, B cells were further purified by negative selection of CD11c + cells or by positive selection for CD19 + cells using MACS columns. B cells were stimulated as indicated by coincubation with CpG (10 mM), activating anti-CD40 (HM40-3) or anti-Ig (187.1) antibodies (5 mg ml -1 ), or LPS (10 mg ml -1 ) at 2 Â 10 6 cells per ml in complete RPMI medium (RPMI-1640, 10% FBS, 100 U penicillin, 100 U streptomycin, 50 mM 2-mercaptoethanol; Invitrogen, Carlsbad, CA, USA). Bone marrow-derived DCs were prepared from harvested bone marrow cells by 8 day incubation in the presence of 20 ng ml -1 GM-CSF (R&D systems, Minneapolis, MN, USA) as described 69 and either unstimulated or stimulated with LPS (10 mg ml -1 ) for 20 h prior use. Flow cytometry was performed according to manufacturer's directions (BD).
T-cell proliferation assay in vitro
OVA-specific TCR-transgenic T lymphocytes were purified from spleens and lymph nodes of OT-1 or OT-2 mice using Pan-T-cell kit (Miltenyi Biotec). Fresh unstimulated B cells or B cells stimulated for 20 h with indicated agents were coated for 2 h with 10 mM of OVA-1 and OVA-2 peptides in complete RPMI medium and irradiated at 2500 rads; 5 Â 10 4 OT-1 or OT-2T cells were co-incubated with sequential dilutions of B cells for 72 h. T-cell proliferation was determined by [ 3 H]-thymidine incorporation. 69, 70 Cytokine production in vitro B cells were incubated for 24 h at 2 Â 10 6 per ml in complete RPMI medium in the presence or absence of stimulators. In mixed cultures, 2.5 Â 10 4 irradiated B cells were co-incubated with 5 Â 10 4 OT-1 or OT-2T cells in 200 ml complete medium for 72 h. Concentration of cytokines was determined using mouse IL-10, 12(p70), IL-4, and IFN-g ELISA sets (BD).
T-cell proliferation in vivo
OT-1 and OT-2T cells were labeled with 5 mM CFSE (Molecular Probes, Eugene, OR, USA); 10 6 OT-1 and OT-2 cells were injected IV into B6.SJL (CD45.1 + ) mice. Twenty-four hours later, 10 6 B6-derived B cells unstimulated or stimulated with indicated agents for 20 h were pulsed for 2 h with OVA-1 and OVA-2 peptides (10 mM) and injected into recipients. Three days later, CFSE dilution in CD45.2 + CD8 + (OT-1) or CD45.2 + CD4 + (OT-2) cells isolated from spleen, PLN and MLN of recipient mice was analyzed by flow cytometry.
Immunization and intracellular cytokine staining
Mice were immunized by intravenous (tail vein) injection of indicated numbers of unstimulated or stimulated OVA-transgenic B cells or B6-derived B cells pulsed for 2 h with cognate OVA-1 and OVA-2 peptides (10 mM) in 200 ml of RPMI. To detect OVA-specific T cells, splenocytes or PBMCs were incubated with OVA-1-specific pentamer (ProImmune, Springfiled, VA, USA) and CD8 antibodies. 70 For ICS, 10 6 splenocytes or PLN or MLN cells were incubated with OVA-1 and OVA-2 peptides (10 mM) and stained intracellularly with IFN-g-FITC antibody as described. 69, 70 For immunization with transfected B cells, CpG/ CD40-stimulated B cells were co-nucleofected with pCMV-1 plasmids (Gene Therapy Systems, San Diego, CA, USA) encoding EGFP and OVA under the control of a CMV promoter (2 mg of each plasmid/2 Â 10 6 cells). Control sample was nucleofected with phCMV1-EGFP and empty phCMV1 plasmid. Nucleofection was done using a Nucleofector II device (Amaxa, Cologne, Germany) according to a protocol optimized for primary mouse B cells (mouse macrophage buffer, Y-001 program). Transfection efficacy in activated cells ranged at 60 to 80%, viability ranged from 50 to 60%. Twenty-four hours post-nucleofection, transfected B cells expressed equal or higher amount of OVA protein compared with OVA-transgenic cells, as determined by western blot analysis. For immunization, viable EGFP + cells were sorted 24 h post-nucleofection and 5 Â 10 4 cells were injected intravenously.
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In vivo cytotoxicity assay
Nine days after immunization, mice were injected with 10 7 autologous splenocytes labeled with 0.35 mM CFSE (control) and 10 7 splenocytes labeled with 3.5 mM CFSE and pulsed with 10 mM specific peptide for 2 h (target population). The spleens and PLN and MLN were harvested 20 h later and the relative killing of target cells was determined as the ratio between the target and control populations standardized against non-immunized controls.
B-cell homing assays
A total of 3 Â 10 6 B cells labeled with 5 mM CFSE were injected intravenously into recipients, and 4 h later, spleens, peripheral blood, PLNs, MLNs and PP were harvested. The frequency of CFSE + CD19 + positive cells was determined by flow cytometry. To investigate the role of CD62L in B-cell homing, a CD62L-SR was designed in which the cleavage is inhibited by a substitution of the membrane-proximal region of CD62L with that of P-selectin by PCR-based mutagenesis (Figure 6c ). 35 CpG/CD40-stimulated B cells were conucleofected with plasmids encoding EGFP and CD62L or CD62L-SR under the control of CMV promoter. Nucleofection was performed on a Nucleofector II. Transfection efficacy in activated cells ranged at 60-80%, viability was about 50-60%. For homing assay, EGFP + cells were sorted, co-labeled with 5 mM CFSE, and 5 Â 10 5 cells were injected intravenously.
Tumor protection assay
Mice were inoculated subcutaneously in left flank with 10 6 thymoma-derived EG-7 cells expressing OVA and 3 and 6 days later immunized intravenously with 10 5 fresh or activated OVA-transgenic B cells, OVA-transgenic bone marrow-derived DCs, or OVA-1 and OVA-2 peptide-pulsed B cells. Tumor size was monitored every 2 days by measuring two perpendicular diameters, and the tumor volume was calculated using the formula: (width) 2 Â length.
Statistical analysis
All reported P-values are two sided. Group comparisons were performed using the Mann-Whitney rank sum test. Correlations were performed using Spearman rank sum test. The SigmaStat (SPSS, Chicago, IL, USA) and NCSS (NCSS, Kaysville, UT, USA) statistical software packages were used.
